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Abstract Genome-wide association studies of prostate
cancer have identiﬁed single nucleotide polymorphism
(SNP) markers in a region of chromosome 10q11.2, har-
boring the microseminoprotein-b (MSMB) gene. Both the
gene product of MSMB, the prostate secretory protein 94
(PSP94) and its binding protein (PSPBP), have been pre-
viously investigated as serum biomarkers for prostate
cancer progression. Recent functional work has shown that
different alleles of the signiﬁcantly associated SNP in the
promoter of MSMB found to be associated with prostate
cancer risk, rs10993994, can inﬂuence its expression in
tumors and in vitro studies. Since it is plausible that
additional variants in this region contribute to the risk of
prostate cancer, we have used next-generation sequencing
technology to resequence a *97-kb region that includes the
area surrounding MSMB (chr10: 51,168,025–51,265,101) in
36 prostate cancer cases, 26 controls of European origin,
and 8 unrelated CEPH individuals in order to identify
additional variants to investigate in functional studies. We
identiﬁed 241 novel polymorphisms within this region,
including 142 in the 51-kb block of linkage disequilibrium
(LD) that contains rs10993994 and the proximal promoter
of MSMB. No sites were observed to be polymorphic
within the exons of MSMB.
Introduction
Genome-wide association studies (GWAS) have been
instrumental in identifying novel regions of the genome that
are associated with human diseases and traits (Donnelly
2008; Manolio et al. 2008). Though prostate cancer has a
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DOI 10.1007/s00439-009-0723-9high incidence rate (*170 per 100,000 men in the United
States) (Crawford 2003), until recently, the only well-
established risk factors for prostate cancer were male sex,
African ancestry, age, and family history (Johns and
Houlston 2003). Genetic factors have been postulated to
contribute to disease, and twin studies have shown high
heritability (Lichtenstein et al. 2000). However, candidate
gene association studies and early linkage analyses yielded
inconclusive results. Recently, GWAS have identiﬁed at
least 20 common genetic variants associated with pros-
tate cancer risk (Amundadottir et al. 2006; Eeles et al.
2008; Freedman et al. 2006; Gudmundsson et al. 2007a, b;
Haiman et al. 2007; Thomas et al. 2008; Yeager et al. 2007).
These ﬁndings have forged new avenues for prostate cancer
researchers to investigate regions that contribute to prostate
cancer risk through yet to be deﬁned mechanisms.
Two independent prostate cancer GWAS identiﬁed a
single-nucleotide polymorphism (SNP; rs10993994 C[T)
on chromosome 10q11.2, which maps to the proximal
promoter of the microseminoprotein-b gene (MSMB)
(Eeles et al. 2008; Thomas et al. 2008). The protein
encoded by MSMB, prostate secretory protein 94 (PSP94),
and its binding protein (PSPBP), have been evaluated as
markers for early detection (Nam et al. 2006) and prognosis
of prostate cancer (Bjartell et al. 2007; Reeves et al. 2006).
The T allele of rs10993994 is signiﬁcantly associated with
the risk of prostate cancer (P = 9.7 9 10
-19;O R= 1.20)
(Lou et al. 2009), and follow-up work has shown evidence
that alleles of rs10993994 differentially inﬂuence the
expression of MSMB (Chang et al. 2009; Lou et al. 2009).
While the C allele was shown to be required for MSMB
expression, the T allele was associated with lower
expression levels of MSMB in vitro (Lou et al. 2009).
Interestingly, these results are consistent with the obser-
vation that MSMB expression levels progressively decrease
during the development of prostate cancer from early
to late stages (LaTulippe et al. 2002; Stanbrough et al.
2006; Vanaja et al. 2003). Together, these data provide a
plausible mechanism for the contribution of the T allele to
prostate cancer risk.
While there is strong evidence that variation at
rs10993994 inﬂuences both MSMB expression and prostate
cancer risk, it is possible that other genetic variants within
this region of chromosome 10q14 could contribute to risk
of developing prostate cancer, perhaps altering MSMB
expression or through other mechanisms (Lou et al. 2009).
Without a comprehensive assessment of common genetic
variation across this region of 10q11.2, it is not possible to
deﬁne the set of high priority common variants suitable for
follow-up studies. In order to comprehensively catalog
common genetic variation across MSMB and the neighbor-
ing region deﬁned by the structure of the linkage disequi-
librium, we used Roche-454 next-generation sequencing
technology (Rothberg and Leamon 2008; Yeager et al.
2008) to resequence, in 70 unrelated individuals, a 97-kb
region of chromosome 10 (chr10: 51,168,025–51,265,101)
that includes a large block (51 kb) of linkage disequilibrium
(LD) in which rs10993994 resides, MSMB, and a neigh-
boring gene, nuclear receptor coactivator 4 (NCO4), that is
also a possible candidate gene for prostate cancer risk.
Materials and methods
Samples
For sequence analysis, 38 prostate cancer cases and 27
controls were selected from the National Cancer Institute’s
(NCI) prostate, lung, colorectal, and ovarian (PLCO) can-
cer screening trial (Gohagan et al. 2000); all (97%) but two
were included in the initial prostate cancer GWAS (Yeager
et al. 2007) that was previously conducted as a part of the
Cancer GEnetics Markers of Susceptibility (CGEMS; see
http://cgems.cancer.gov/) initiative. Additionally, 11 indi-
viduals from CEPH pedigrees were used in the analysis,
including two sets of relatives. Seven of these individuals
were CEU samples from The International HapMap Project
(http://hapmap.org).
Region selection
Using CEU data obtained from the International HapMap
Project (http://www.hapmap.org; The International HapMap
Consortium 2005), based on the pattern of linkage disequi-
librium (LD) ﬂanking rs10993994 using Haploview (Barrett
et al. 2005), we targeted 97 kb (chr10: 51,167,932–51,
265,146),whichincludeda51-kbblockofLDcentromericof
MSMB with rs10993994 at its most telomeric position but
noneofthe codingexons.Weextendedourtargetsequencing
by an additional 46 kb to include MSMB and the telomeric
neighboring gene, nuclear receptor coactivator 4 (NCOA4).
PCR primer design
Twenty sets of long-range PCR primers were designed to
cover the 97-kb targeted region. Approximate amplicon size
ranged from 3,544 to 5,542 bp; primer sets were designed to
overlap, and averaged 292 bp overlap with the adjacent
primer set. Primer design was as follows: primers had been
initially designed using Primer3 (http://frodo.wi.mit.edu)
(Rozen and Skaletsky 2000), were then quality-checked in
silico for uniqueness, potential sequence paralogy and DNA
repeat sequences using the BLAT feature of the UCSC
genome browser (http://genome.ucsc.edu/cgi-bin/hgBlat).
Next, NetPrimer (http://www.premierbiosoft.com/netprimer/
index.html)wasusedtocheckforprimersecondarystructures
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Technologies (Coralville, IA, USA; http://www.idtdan.com).
Allprimers,coordinates,andPCRconditionsaresuppliedin
Supplementary Table 1.
Sequencing
Post long-range PCR, all protocols were followed in accor-
dance to standard kits used for the 454 GS FLX system
(http://www.454.com/products-solutions/product-list.asp).
Polymorphism detection
An automated computational pipeline was developed to
process sequence reads generated by 454 FLX genome
sequencers. Whenever applicable, sequence reads from the
same sample were pooled based on barcodes provided by
Roche/454. QC was performed with vendor-supplied soft-
ware, andsequencereadsthatpassedQCwere aligned tothe
target genomic region (chr10: 51,167,932–51,265,146) by
MOSAIK software (http://bioinformatics.bc.edu/marthlab/
Mosaik). The resulting assembly was analyzed in a column-
by-column approach and potential polymorphic sites and
most likely genotypes were called based on a set of heuristic
rules. For each nucleotide position, the minimal sequence
coverage depth was set to 20 reads. In addition, the ratio (r)
of forward and reverse reads was determined. To avoid
directional bias, an optimal range of r was set between 10
and 90%. Homozygous genotype calls were made when the
most frequent allele was present in at least 85% of the reads.
Heterozygous genotype calls were made when the two most
frequent alleles were represented in 30–70% of reads. No
genotype calls were made if the above criteria were not met.
Manual inspections aided by the NextGENe software
(http://www.softgenetics.com)andConsed(http://bozeman.
mbt.washington.edu/consed/consed.html) were performed
to QA the results and resolve ambiguous cases.
Descriptive statistics
Completion, concordance, minor allele frequency (MAF)
estimations, deviations from ﬁtness for Hardy–Weinberg
proportion (HWP), pair-wise LD, and tag SNP selection
were computed using the GLU software package (http://
code.google.com/p/glu-genetics/).
Results
Coverage and depth
Excellent coverage and depth was obtained across the entire
sequenced region. Figure 1 shows the coverage and depth
averaged across all samples. The average depth was 104X,
with a minimum of 24X; in two small regions (chr10:
51,177,997–51,183,539 and 51,241,521–51,246,917) that
correspond to two amplicons we consistently observe an
average coverage depth of \50X, though in both regions
coverage did not fall below 25X.
We consistently observed over-representation of sequence
reads at the ends of amplicons, regardless of the genomic
regions or individual samples sequenced. The coverage vari-
ability was as high as three or more times the average, an
artifact that is most likely introduced during the shotgun
sequencinglibrarypreparationofPCRamplicons(Harismendy
and Frazer 2009). Another contributing factor to the ‘‘spikes’’
in Fig. 1 is that adjacent amplicons are usually overlapped at
the ends, which increases the chance of sequence over-
sampling.
Polymorphism detection and genotype and sample
quality control
The heuristic rules we implemented (‘‘Materials and meth-
ods’’) took into consideration uneven sequence coverage.
Therefore, coverage spikes at the amplicon ends (Fig. 1)
have minimal impact on genotype accuracy. Genotypes
were initially called for 685 SNPs and insertion/deletion
polymorphisms (indels) in 76 individuals, including sites
that had been previously reported in the NCBI dbSNP data-
base (http://www.ncbi.nlm.nih.gov/projects/SNP/). Itera-
tions of data cleaning excluded two related CEPH
individualsand41lociwithsigniﬁcantgenotypeissues(e.g.,
failure of Hardy–Weinberg proportions; P\0.001) and/or
with very low (\50%) genotype calling (completion) rates;
11 of these 41 polymorphisms fell within the chr10:
51,241,521–51,246,917regionofloweraveragecoverageas
discussed above. Within the other region of lower-than-
average coverage, genotypes were successfully obtained for
18 loci, and the observed heterozygosity within this interval
did not differ than the average across other regions. Of the
remaining 637 loci, 190 sites in dbSNP were observed to be
monomorphic within our samples and were excluded for
subsequent analyses.
Utilizing the CGEMS prostate follow-up #2 iSelect
(manuscripts in progress), we examined the 27 SNPs that
overlapped the sequence data in 41 PLCO samples. In three
samples, genotype concordance rates were \75%, all of
which had low completion rates; all other samples were
100% concordant. After removing these three samples,
genotype concordance per locus was 100% (Supplementary
Table 2). Data from the International HapMap Project
(http://www.hapmap.org) were used for 70 SNPs geno-
typed within this region over the seven HapMap CEU
individuals. One sample displayed\95% concordance and
was removed from further analyses. Concordance for two
Hum Genet (2009) 126:743–750 745
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all individuals displaying discordant genotypes; these two
SNPs were excluded from further analyses. Three other
SNPs displayed one discordant genotype each, and the
remaining 65 SNPs displayed 100% concordance between
HapMap genotypes and genotypes derived by sequencing.
Final dataset statistics
The ﬁnal genotype dataset contained 70 individuals (36 and
26 PLCO prostate cancer cases and controls, respectively,
and 8 unrelated CEPH individuals) and 440 polymorphic
loci. The average call rate for genotypes was 92% (range
50–100%; median 97%; see Supplementary Table 2).
Minor allele frequency (MAF) estimates were computed
for each SNP and indel and overall averaged 15% (range
0.7–50%; see Supplementary Table 2); MAF by chromo-
somal position is shown in Fig. 2. Overall, 181 sites (169
SNPs and 12 indels) were observed to have a MAF C 5%
(Table 1). A total of 115 SNPs and 44 indels were observed
in only one chromosome each. Since our indel-calling
algorithm is currently still being reﬁned, these low-fre-
quency variants should be treated as preliminary; we
include them here for completeness of probable polymor-
phic sites.
Table 1 shows the classiﬁcation of SNPs and indels with
respect to previous dbSNP, HapMap, and Illumina
HumanHap610 inclusion. Of the 440 polymorphic loci, 199
had previously been reported in the dbSNP database, only
84 of which contained available frequency information in
dbSNP at the time of analysis (see Table 1). Within this
region, 68 SNPs were genotyped as a part of the HapMap
Project (http://www.hapmap.org), and 16 SNPs are inclu-
ded on the Illumina HumanHap610 ﬁxed-content GWAS
chip. In this study, we observed 241 novel SNPs and indels,
of which 98 SNPs and 44 indels were observed as single-
tons and many others relatively rarely (\5% MAF).
No novel polymorphic sites were observed within the
exons of the MSMB gene, nor were any of the exonic SNPs
that had been previously reported (N = 24 in dbSNP)
observed to be polymorphic within our samples. For
NCOA4, no sites were observed to be polymorphic within
the ﬁrst six exons. However, within exons 7, 8, and 10
there were 2, 3, and 4 polymorphic sites observed,
respectively. Supplementary Table 3 includes the subset of
variants observed within the exons of the NCOA4 gene. Of
the observed polymorphic sites, two were synonymous
Fig. 1 Coverage and depth
averaged over all samples for
the 97-kb region of
chromosome 10q11.2. The
region consists of chr10:
51,167,932–51,265,146), which
includes a 51-kb block of LD
centromeric of MSMB with
rs10993994 at its most
telomeric position
Fig. 2 Minor allele frequencies by position for all polymorphic
variants across the 97 kb of chromosome 10q11.2. All polymorphic
sites are included across chr10: 51,167,932–51,265,146
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123changes, tree non-synonymous, and four fell within the
30UTR of the gene; all but two of the SNPs were observed
in only one chromosome apiece (rs41306524, D223D;
rs11548236, 30UTR).
Linkage disequilibrium and tag SNP selection
An extremely high degree of LD was observed among
polymorphic sites within the ﬁrst 51 kb of the 97 kb
sequenced region (Fig. 3; values shown are r
2). This region
contains the previously associated functional SNP,
rs10993994, as well as the proximal promoter of MSMB.
Outside of this large block, signiﬁcant LD was not
observed within the region containing MSMB and NCOA4.
Tagging analysis of the 97-kb region at an r
2 of 0.8 with
rs10993994 as an obligate-include gave a total of 36 tags
necessary to cover the 181 loci with a MAF[5% in
individuals of European background. The bin containing
rs10993994 contains 20 other SNPs but no indels. Sup-
plementary Table 4 shows the pairwise r
2 of these SNPs
ranges from 0.8 to 0.85. It is notable that no other variant
was observed to be completely correlated with rs10993994.
Tagging at more aggressive r
2 thresholds of 0.9 and 1.0
increased the number of tags to 39 and 116, respectively.
Supplementary Table 5 lists the bin and tag SNP infor-
mation using three thresholds: r
2 C 0.8, r
2 C 0.9, and
r
2 = 1.0.
In order to determine the overall contribution of the
newly described variants from this study with respect to
coverage of the 97 kb region, we tagged (r
2 C 0.8, mini-
mum MAF = 5%) based on prior inclusion of SNPs and
indels in dbSNP, both (1) with and (2) without reported
frequency information, (3) inclusion in HapMap, (4)
inclusion on the Illumina HumanHap610 ﬁxed-panel
GWAS chip, and (5) novel variants discovered as a part of
this effort. In total, 154 SNPs and 5 indels reported in
dbSNP (http://www.ncbi.nlm.nih.gov/SNP) provide 83%
bin coverage (Table 1) of the region. However, since the
majority of these SNPs (N = 108) contained no frequency
information within the database, this study provides further
characterization for these predicted variants. A subset
(N = 58) of dbSNP SNPs were characterized as a part
of the International HapMap Project (http://www.hapmap.
org), and only provide 50% bin coverage of the 97-kb
region. An even smaller subset of SNPs (N = 16) are
included on the widely used Illumina HumanHap610 ﬁxed
Table 1 Distribution of polymorphic SNPs and indels with regards to Illumina HumanHap610, dbSNP and HapMap inclusion
Content
a SNPs Indels % bin coverage Untagged bins
c
All [5%
b All [5%
b
dbSNP 127
a 191 154 8 5 83.3 6
No prior frequency information 108 84 7 4 55.6 16
Prior frequency information 83 70 1 1 55.6 16
HapMap I ? II
a 68 58 0 0 50 18
Illumina HumanHap610
a 16 16 0 0 27.8 26
Novel 157 15 84 7 33.3 24
All variants 348 169 93 12 100 0
169 dbSNP SNPs were found to be monomorphic within our samples
a Illumina HumanHap610, HapMap I ? II, and dbSNP SNPs overlap since all SNPs are included in dbSNP
b Minor allele frequency, MAF
c Number of additional tags required to monitor the remaining variation
Fig. 3 Linkage disequilibrium
(LD) of polymorphisms C5%
MAF as measured by r
2 across
a 97-kb region of chromosome
10q11.2. Relative locations of
rs10993994, MSMB, and
NCOA4 are shown, though not
to scale. Coordinates based on
NCBI genome build 36.3
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coverage. Considering only the 22 common ([5% MAF)
SNPs discovered by our resequencing project, these novel
variants provide 33% bin coverage. All SNPs and indels
taken together, regardless of source, provide 100% cover-
age of this region, and will be extremely useful in studies
focused on this region of the genome.
Discussion
In this study, we have characterized the set of common
SNP and indel variants across a 97-kb region of chromo-
some 10q11.2, and in the process have doubled the number
of variants available for follow-up in individuals of Euro-
pean background. It is notable that we did not discover
additional SNPs or indels in perfect LD with rs10993994,
the promoter SNP most strongly associated with prostate
cancer risk in two independent GWAS, which has also
been shown to display a molecular phenotype consistent
with decreased expression of MSMB. Consequently, our
ﬁndings further point toward rs10993994 as the probable
variant that at minimum partially accounts for the associ-
ation with prostate cancer. Our analysis also provides a
comprehensive portrait of common variation across this
region. Tagging of the region with an r
2 threshold of 0.8 for
variants with a MAF[5%, 36 variants are required, but
tagging at more aggressive r
2 thresholds of 0.9 and 1.0
increased the number of tags to 39 and 116, respectively.
There is increasing evidence that the microseminopro-
tein-b (MSMB) gene on chromosome 10q11.2 plays a role
in the development of prostate cancer. GWAS studies have
pointed to this region and follow-up studies have shown
that altered gene expression of MSMB, as a consequence of
the most signiﬁcantly associated variants in the promoter,
correlated with prostate cancer risk. Levels of MSMB
reportedly are decreased in patients with poorer outcome
and higher cancer recurrence (Nam et al. 2006; Reeves
et al. 2006). Furthermore, the protein encoded by MSMB
has been shown to suppress the growth and induce apop-
tosis of prostate cancer cells (Lokeshwar et al. 1993;
Mundle and Sheth 1993) Though strong evidence suggests
that alleles of rs10993994 are functionally important
(Chang et al. 2009; Lou et al. 2009) and account for a
portion of prostate cancer susceptibility (Chang et al. 2009;
Eeles et al. 2008; Lou et al. 2009; Thomas et al. 2008), it is
also plausible that other variants in this region of chro-
mosome 10q11.2, perhaps in other genes such as NCO4,
could further contribute to risk (Lou et al. 2009).
Using 454 next-generation sequencing technology
(Rothberg and Leamon 2008), we have extensively char-
acterized common genetic variation across this region of
chromosome 10q11.2, which includes the MSMB gene and
a large upstream block of LD that contains its proximal
promoter and the SNP for which functional alleles have
been described, rs10993994 (Chang et al. 2009; Lou et al.
2009). Though 24 exonic variants are reported in the
dbSNP database, no polymorphic variants were conﬁrmed
within the exons of the MSMB gene. Within the *51-kb
block of LD that contains rs10993994 and the proximal
promoter of MSMB, we characterized 282 genetic variants,
including 94 and 49 novel SNPs and indels, respectively.
As a part of this project, we also included the
sequencing of a neighboring gene, nuclear receptor coac-
tivator 4 (NCOA4, also known as ARA70). MSMB and
NCOA4 are physically located *10 kb apart, and NCOA4
may also be of interest in prostate cancer since it is a
coregulator of androgen receptor (AR) (Yeh and Chang
1996). The ARA70 protein has at least two known isoforms
(a and b), both of which may have effects on prostate
cancer growth though through potentially different mech-
anisms. ARA70a inhibits androgen-dependent cell prolife-
ration, and ARA70b promotes proliferation and enhances
prostate cancer invasion (Peng et al. 2008). In addition to
observing an association with rs10993994, Chang et al.
(2009) observed a potential second region of association
(represented by rs10761581) in a block of LD across
NCOA4 that was separated from rs10993994 by a recom-
bination hotspot (Chang et al. 2009), though the association
was not consistent across all replication studies. Common
genetic variation in this region should be further explored
for independent evidence of association with prostate
cancer; a precedent has already been set for multiple
independent associations in close proximity from prostate
cancer GWAS, including 8q24 (Gudmundsson et al. 2007a;
Haiman et al. 2007; Yeager et al. 2007) and HNF1B (Sun
et al. 2008).
The relationship between the two contiguous genes on
chromosome 10q11.2, MSMB and NCO4 could be com-
plex. In the National Center for Biotechnology Information
(NCBI) public database AceView (http://www.ncbi.nlm.
nih.gov/IEB/Research/Acembly/) (Thierry-Mieg and Thierry-
Mieg 2006)), also displayed within the UCSC genome
browser (http://genome.ucsc.edu/) (Kent et al. 2002),
MSMB and NCOA4 form a complex locus in which mRNA
transcripts utilize exons from both genes. For example,
expressed sequence tag (EST) DB215804.1 (Kimura et al.
2006) is comprised of exons 1 and 2 of MSMB and exons
2–4 of NCOA4. Therefore, the MSMB promoter could
affect the regulation of hybrid MSMB-NCOA4 proteins. It
will be important to further explore the role of genetic
variation at NCOA4 and prostate cancer risk.
We have characterized common genetic variation across
*97 kb of chromosome 10 (chr10: 51,168,025–51,265,101)
thatisof immediateinterestin prostatecancerresearch, since
it is comprised of (1) a region of linkage disequilibrium (LD)
748 Hum Genet (2009) 126:743–750
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resides, (2) a strong candidate gene for prostate cancer risk
(MSMB), and (3) an additional gene (NCOA4)t h a ti so f
interest in prostate cancer and parts of which that may, in
somecases,betranscribedwithexonsfromMSMB.Co mm on
and uncommon variants identiﬁed in this comprehensive
resequenceanalysis ofa regionofchromosome10q11.2have
established a foundation for choosing tag SNPs in follow-up
studies to further map the region in an effort to nominate the
most likely candidate variants for follow-up functional labo-
ratory work to investigate the molecular basis of prostate
cancer risk in this region.
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